Login / Signup

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?

Ammad MahmoodKeith W Muir
Published in: Current treatment options in neurology (2022)
A single thrombolytic agent for all indications for thrombolysis in acute ischaemic stroke is desirable in streamlining workflows. Based on recent and upcoming trials, guidelines may soon recommend tenecteplase as a suitable alternative to alteplase. The use of tenecteplase in specific subgroups will depend on further recruitment to ongoing clinical trials.
Keyphrases
  • acute ischemic stroke
  • pulmonary embolism
  • clinical trial
  • liver failure
  • respiratory failure
  • current status
  • drug induced
  • phase ii
  • open label
  • acute respiratory distress syndrome
  • phase iii